The Amyloidosis Channel is supported with funding from Prothena (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Updated results with the bispecific antibody etentamig in patients with R/R AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, presents data from the Phase I dose escalation portion of a study (NCT06158854) investigating the BCMAxCD3 bispecific antibody etentamig in patients with relapsed/refractory (R/R) light chain (AL) amyloidosis. Prof. Sanchorawala notes that the results with this agent are highly encouraging thus far, with deep and rapid hematologic responses being observed. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Etentamig is a second-generation BCMAxCD3 bispecific antibody and it is a very, very interesting molecule with dual BCMA binding sites, also very low CD3 affinity binding site, and a silenced Fc portion making the half-life of this molecule longer to allow us to dose this medication every four weeks. So, etentamig was studied in phase 1b, phase 2 schedule for AL amyloidosis in relapsed/refractory setting...
Etentamig is a second-generation BCMAxCD3 bispecific antibody and it is a very, very interesting molecule with dual BCMA binding sites, also very low CD3 affinity binding site, and a silenced Fc portion making the half-life of this molecule longer to allow us to dose this medication every four weeks. So, etentamig was studied in phase 1b, phase 2 schedule for AL amyloidosis in relapsed/refractory setting.
The data that was presented at this meeting were on 34 patients who were enrolled on phase 1b dose escalation phase of the study. The doses were 20 milligrams, 40 milligrams and 60 milligrams which were administered every four weeks. This was a fixed-duration treatment schedule of 24 cycles. And 34 patients really had a very high hematologic responses on this schedule, overall hematologic complete response was 82% and VGPR was 18% with an overall response rate of 100% in patients with refractory/relapsed AL amyloidosis. This deep hematologic responses occurred at a median of 29 days, so very, very rapid responses and this led to also organ responses in approximately 50% of patients.
Moreover, the safety profile was quite favorable. CRS rate was extremely low at less than 10% and grade 3, 4 infections occurred in about one patient out of 34, that’s 2.9%. And there were no delays or toxicities as well as no neurotoxicities. So, this is a very, very exciting time and very well-tolerated specific antibody for relapsed AL amyloidosis.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
